Dr. Gandara on Measuring TMB in NSCLC

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, discusses measuring tumor mutational burden (TMB) in patients with non–small cell lung cancer (NSCLC) who received prior immunotherapy.

Through a host of research tests and comprehensive genomic profiling, TMB can be measured in many ways to determine a patient’s response to immunotherapy, says Gandara. 

Three examples include the FoundationOne CDx test in tissue, as well as the Guardant OMNI and FoundationOne Liquid tests in blood. The blood tests, though not commercially available, are currently under development, Gandara concludes.